Đánh giá hiệu quả kiểm soát đường huyết giữa nhóm thuốc ức chế men Dipeptidyl peptidase-4 và nhóm thuốc ức chế kênh đồng vận chuyển Natri-Glucose 2 trên bệnh nhân đái tháo đường tuýp 2 tại Bệnh viện Nhân dân Gia Định=Evalution of glucose lowering efficacy between Dipeptidyl Peptidase-4 inhibitors (DPP-4) and Sodium-Glucose cotransporter-2 inhibitors (SGLT-2) in type 2 diabetes mellitus patients at Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Chi Nguyễn, Hồng Thắm Phạm

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Khoa học và Công nghệ - Đại học Nguyễn Tất Thành, 2024

Mô tả vật lý: tr.167

Bộ sưu tập: Metadata

ID: 249346

Thêm vào giỏ

In Viet Nam, the use of SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes is limited. The study was conducted to evaluate the treatment efficacy between SGLT-2 inhibitors and DPP-4 inhibitors on blood sugar control. Descriptive cross-sectional study, 6-month follow-up was performed in type 2 diabetes patients from January 2024 to June 2024 at Nhan Dan Gia Dinh Hospital. Results have shown that over 80 % of patients were treated with metformin combination therapy. The most commonly prescribed active ingredient in the SGLT-2 inhibitor group is Empagliflozin with 70.40 %, followed by Dapagliflozin with 29.60 %. The most commonly prescribed active ingredient in the DPP-4 inhibitor group is Sitagliptin with 65.00 %, followed by Vildagliptin with 23.30% and Linagliptin with 11.70 %. The difference in glycemic control and HbA1c reduction after 6 months was not statistically significant between the SGLT-2 inhibitor group and the DPP-4 inhibitor group ((1.20 ± 0.80) % vs (1.10 ± 0.70) %, respectively, p >
0.05). Both groups showed effectiveness in controlling blood sugar in patients and did not increase the risk of hypoglycemia. There is a relationship between blood sugar and cardiovascular outcomes in type 2 diabetic patients.Tại Việt Nam, nhóm thuốc ức chế kênh đồng vận chuyển Natri-Glucose 2 và nhóm thuốc ức chế men Dipeptidyl peptidase-4 sử dụng trên bệnh nhân đái tháo đường tuýp 2 vẫn còn hạn chế. Nghiên cứu được thực hiện với mục tiêu đánh giá hiệu quả điều trị giữa nhóm thuốc ức chế kênh đồng vận chuyển Natri-Glucose 2 và nhóm thuốc ức chế men Dipeptidyl peptidase-4 trong việc kiểm soát đường huyết. Nghiên cứu cắt ngang mô tả trên bệnh nhân đái tháo đường tuýp 2 trong khoảng thời gian từ tháng 1-2024 đến tháng 6-2024 tại Bệnh viện Nhân dân Gia Định. Kết quả cho thấy, đa số bệnh nhân sử dụng liệu pháp kết hợp với metformin (trên 80 %), hoạt chất được chỉ định nhiều nhất trong nhóm ức chế kênh đồng vận chuyển Natri-Glucose 2 là empagliflozin với 70,40 %, kế tiếp là dapagliflozin với 29,06 %
hoạt chất được chỉ định nhiều nhất trong nhóm ức chế men Dipeptidyl peptidase-4 là sitagliptin với 65,00 %, kế tiếp là vildaglitin với 23,30 % và cuối cùng là linagliptin chiếm 11,70 %. Cả hai nhóm đáp ứng hiệu quả trong việc kiểm soát đường huyết và không làm tăng nguy cơ hạ đường huyết.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR